Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61M-035/00
A61K-031/135
A61K-031/17
A61K-031/192
A61K-031/27
A61K-031/4164
A61K-031/42
A61K-031/428
A61K-031/435
A61K-031/4436
A61K-031/445
A61K-031/47
A61K-031/498
A61K-031/505
A61K-031/55
A61K-031/704
A61M-037/00
A61N-001/30
A61K-031/137
A61K-031/155
A61K-031/165
A61K-031/415
A61K-031/4439
A61K-031/473
A61K-031/4965
A61K-031/7072
A61K-031/708
출원번호
US-0268725
(2014-05-02)
등록번호
US-9669199
(2017-06-06)
발명자
/ 주소
DiPierro, Guy
Giannos, Steven A.
출원인 / 주소
Chrono Therapeutics Inc.
대리인 / 주소
Shay Glenn LLP
인용정보
피인용 횟수 :
2인용 특허 :
117
초록▼
Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and t
Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, plant extracts, botanicals, nutraceuticals, cosmeceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.
대표청구항▼
1. A method for delivering nicotine to a human comprising: delivering the nicotine dissolved in a solvent to a skin-interface membrane of a transdermal drug delivery device coupled to skin of the human; absorbing the nicotine from the skin-interface membrane transdermally into the human; moving solv
1. A method for delivering nicotine to a human comprising: delivering the nicotine dissolved in a solvent to a skin-interface membrane of a transdermal drug delivery device coupled to skin of the human; absorbing the nicotine from the skin-interface membrane transdermally into the human; moving solvent from the skin-interface membrane into a solvent removal element comprising a desiccant or absorbent material of the transdermal drug delivery device; and repeating the delivering, absorbing and moving steps to modulate and control dosing to create a plurality of nicotine blood plasma concentration peaks and troughs in the human over a 16 hour period. 2. The method of claim 1, wherein the nicotine delivery is for treating nicotine addiction. 3. The method of claim 1 wherein the first delivery step is performed immediately before the human wakes up. 4. The method of claim 1 wherein the delivery steps are performed so as to deliver the nicotine at times that are associated with nicotine cravings. 5. The method of claim 4 wherein at least one of the times corresponds to a time at which the human experiences a morning nicotine craving. 6. The method of claim 4, wherein the delivery step comprises delivering a first dosage of nicotine to the human to raise the human's blood plasma concentration of nicotine from a first level to a second level higher than the first level while the human is asleep. 7. The method of claim 6, wherein the delivery, absorbing and moving steps further comprise reducing or stopping delivery of nicotine to the human to reduce the human's blood plasma concentration of nicotine from the second level to a third level lower than the second level, then delivering a second dosage of nicotine to the human to increase the human's blood plasma concentration of nicotine from the third level to a fourth level higher than the third level to offset an expected nicotine craving associated with a meal. 8. The method of claim 7, wherein the delivery, absorbing and moving steps further comprise reducing or stopping delivery of nicotine to the human to reduce the human's blood plasma concentration of nicotine from the fourth level to a fifth level lower than the fourth level, then delivering a third dosage of nicotine to the human to increase the human's blood plasma concentration of nicotine from the fifth level to a sixth level higher than the fifth level. 9. The method of claim 8, wherein the delivery, absorbing and moving steps further comprise reducing or stopping delivery of nicotine to the human to reduce the human's blood plasma concentration of nicotine from the sixth level to a seventh level lower than the sixth level. 10. The method of claim 9, wherein the delivery step further comprises delivering a fourth dosage of nicotine to the human to increase the human's blood plasma concentration of nicotine from the seventh level to an eighth level higher than the seventh level. 11. The method of claim 4, wherein the delivery step comprises delivering a first dosage of nicotine to the human to raise the human's blood plasma concentration of nicotine from a first level to a second level higher than the first level and delivering a second dosage of nicotine to the human to raise the human's blood plasma concentration of nicotine from the second level to a third level higher than the second level. 12. The method of claim 11, wherein the delivery step further comprises delivering a third dosage of nicotine to the human to increase the human's blood plasma concentration of nicotine from the third level to a fourth level higher than the third level. 13. A method for delivering nicotine to a human comprising: delivering the nicotine dissolved in a solvent to a skin-interface membrane of a transdermal drug delivery device coupled to skin of the human; absorbing the nicotine from the skin-interface membrane transdermally into the human; moving solvent from the skin-interface membrane into a solvent removal element of the transdermal drug delivery device; and repeating the delivering, absorbing and moving steps to modulate and control dosing to create a plurality of nicotine blood plasma concentration peaks and troughs in the human over a 16 hour period whereby permeation through the skin is assisted using one or more from the group comprising: micro-fabricated structures, heat, sonophoresis, and a chemical permeation enhancer.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (117)
Nelson, Kyle S.; Bischoff, Brian J., Activity monitoring.
DiPierro, Guy; Giannos, Steven A., Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, Alzheimer'S disease, sleep disorders, Parkinson'S disease, AIDS, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like.
Dipierro, Guy; Giannos, Steven A., Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like.
Nagy Christa F. (Wyckoff NJ) Quick Timothy W. (Clifton NJ) Shapiro Stanley S. (Livingston NJ), Compositions of retinoic acids and tocopherol for prevention of dermatitis.
Hall Bonnie J. (Mason OH) Baur Julie A. (Fairfield OH) Deckner George E. (Cincinnati OH), Dermatological compositions and method of treatment of skin lesions therewith using benzoyl peroxide and tocopherol este.
Fallon Renee A. (Sunnyvale CA) Wilson Donald R. (San Francisco CA), Device for administering drug transdermally which provides an initial pulse of drug.
Lattin Gary A. (Forest Lake MN) Dickson Dale A. (Fridley MN) Grace Michael J. (Coon Rapids MN), Electrotransport agent delivery device having a disposable component and a removable liner.
Orr,Kevin H.; Mankaruse,George S.; Asaria,Ali, Handheld electronic device including vibrator having different vibration intensities and method for vibrating a handheld electronic device.
Klug Reja B. (30 Bay Dr. SE. Fort Walton Beach FL 32548) Ford Richard D. (117 Lake Lorraine Cir. Shalimar FL 32579) Jamison Keith A. (137 Indian Bayou Dr. Destin FL 32541) Stearns Ronald E. (2 Caswel, High energy coaxial cable for use in pulsed high energy systems.
Behar Albert (Reston VA) Behar Orna (Reston VA) Frederiksen Lee W. (McLean VA) Howard-Link Donald A. (Columbia MD) Timmerman Catherine (Washington DC), Human behavior modification which establishes and generates a user adaptive withdrawal schedule.
Edwards, Eric S.; Edwards, Evan T.; Licata, Mark J.; Meyers, Paul F.; Weinzierl, David A., Medicament delivery device having an electronic circuit system.
Segel Joseph M. ; Samuelson Michael H., Method and system for stopping or modifying undesirable health-related behavior habits or maintaining desirable health-.
Cormier Michel J. N. (Palo Alto CA) Ledger Philip W. (Mountain View CA) Amkraut Alfred (Palo Alto CA) Marty Jean P. (Sceaux FRX), Method for reducing sensitization or irritation in transdermal drug delivery and means therefor.
Majeed, Muhammed; Badmaev, Vladimir; Bammi, Rajinder Kumar; Prakash, Subbalakshmi; Natarajan, Sankaran, Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives.
Raheman, Fazal, Prescription zero: a non-pharmaceutical prescription device for prescribing, administering, monitoring, measuring and motivating a therapeutic lifestyle regimen for prevention and treatment of chronic diseases.
Amkraut Alfred (Palo Alto CA) Shaw Jane E. (Atherton CA), Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug.
Ledger Philip W. (Mountain View CA) Cormier Michel J. (Mountain View CA) Amkraut Alfred (Palo Alto CA), Reduction or prevention of sensitization to drugs.
Cormier Michel J-N (Mountain View CA) Ledger Philip W. (Mountain View CA) Amkraut Alfred (Palo Alto CA), Reduction or prevention of skin irritation by drugs.
Cormier Michel (Mountain View CA) Amkraut Alfred (Palo Alto CA) Ledger Philip W. (Bedford GBX), Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensiti.
Osborne James L. (Mountain View CA) Nelson Melinda (Sunnyvale CA) Enscore David J. (Saratoga CA) Yum Su I. (Los Altos CA) Gale Robert M. (Los Altos CA), Subsaturated nicotine transdermal therapeutic system.
Currie, John F.; Paranjape, Makarand; Peck, Carl C.; White, Robert; Schneider, Thomas W., Systems and methods for monitoring health and delivering drugs transdermally.
Haak Ronald P. (Menlo Park CA) Theeuwes Felix (Los Altos Hills CA) Gyory J. Richard (San Jose CA) Lattin Gary A. (Forest Lake MN), Transdermal delivery device.
Bello Gastone P. (Monmouth Beach NJ) Lyle John W. (Belmar NJ) Johnson Donald A. (Sea Girt NJ), Transdermal drug delivery device and method for its manufacture.
Fallon Renee A. (Sunnyvale CA) Venkatraman Subbu S. (Palo Alto CA) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset.
Venktrama Subbu S. (Palo Alto CA) Fallon Renee A. (Sunnyvale CA) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset.
Govil Sharad K. (Plantation FL) Rudnic Edward M. (Boca Raton FL) Sterner Dale G. (Pembroke Pines FL), Transdermal nitroglycerin patch with penetration enhancers.
Quan Danyi (Salt Lake City UT) Deshpanday Ninad A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT), Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
Kang, Sewon; Fisher, Gary J.; Voorhees, John J., Use of natural EGFR inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor.
Heiber Werner (Bedford Hills NY) Andriola Robert (Putnam Valley NY) Williams Paul (Fairlawn NJ) Ebert Charles (Redwood City CA), User-activated transdermal therapeutic system.
DiPierro, Guy; Giannos, Steven A., Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like.
Netzel, Zita S.; Stacey, Gary; Norman, Alexander David; Huang, Congyi; Frearson, Timothy Charles; Kilby, Charles Frazer; Ruane, Patrick H.; Levy, Alan J.; Gelston, Kevin W.; Darmour, Jennifer; Hapgood, Jenny E.; Roth, David Evans; Overbeck, Ronald A.; Tong, Ling-Kang, Drug delivery methods and systems.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.